Latest Benzamides Stories

MISSISSAUGA, ON, Nov. 5, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today reported interim results from the Phase I/II study of CYT387, a JAK1/JAK2 inhibitor currently being evaluated for the treatment of myelofibrosis, which were included in an abstract submitted to the American Society of Hematology in August 2012. Updated results will be presented in an Oral Session at the 2012...

INDIANAPOLIS, Oct. 17, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that patients may receive ALIMTA(®) (pemetrexed for injection) as a maintenance therapy following first-line ALIMTA plus cisplatin for locally advanced or metastatic nonsquamous non-small cell lung cancer (NS NSCLC). The FDA approved the label inclusion of Phase III data that demonstrated progression-free and overall survival advantages in the continuation maintenance setting for these...

PARMA, Italy, October 16, 2012 /PRNewswire/ -- Chiesi Group announces that it has successfully completed a Phase I trial of its inhaled PDE4 (phosphodiesterase 4) inhibitor, denoted CHF 6001, a new chemical entity developed for the treatment of inflammatory respiratory disorders, such as chronic obstructive pulmonary disease (COPD) and asthma. (Logo: http://photos.prnewswire.com/prnh/20121016/568014 ) The phase 1 study was conducted to evaluate safety,...

MISSISSAUGA, ON, Oct. 11, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today announced that the results of its Phase I/II Study of CYT387, a JAK1/JAK2 inhibitor currently being evaluated for the treatment of myelofibrosis, have been selected by the ASH Program Committee for presentation in an Oral Session at the 2012 Annual Meeting of the American Society of Hematology to be held in...

The HIV protease inhibitor, Nelfinavir, can be used to treat HER2-positive breast cancer in the same capacity and dosage regimen that it is used to treat HIV, according to a study published October 5 in the Journal of the National Cancer Institute. Breast cancer is one of the most common causes of cancer deaths in the U.S. with approximately 39,520 women succumbing to the disease in 2011. HER2-postive breast cancer is known to be more aggressive and less responsive to treatments compared...

INDIANAPOLIS, Sept. 29, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from two Phase II ramucirumab (IMC-1121B) trials in patients with non-small cell lung cancer (NSCLC). Results were presented today during the Lung Cancer - Metastatic Poster Session at the ESMO 2012 Congress (European Society for Medical Oncology), 1:00 p.m. - 2:00 p.m. CET, in Vienna, Austria. Interim data for a study in chemotherapy-naive patients with advanced NSCLC treated...

- Completed dosing for 166 patient CYT387 Phase I/II nine-month trial - - Completed enrolment of 61 patient CYT387 Phase II BID trial - MISSISSAUGA, ON, Sept. 21, 2012 /PRNewswire/ - YM BioSciences Inc. (NYSE MKT: YMI, TSX: YM), a drug development company advancing hematology and cancer related products, today reported operational and financial results for its 2012 fiscal year, ended June 30, 2012. "We made significant progress with CYT387 during Fiscal 2012, highlighted by...

BEDFORD, Ohio, Sept. 18, 2012 /PRNewswire/ -- Bedford Laboratories((TM)) today announced the expansion of its previous nationwide voluntary recall for Leucovorin Calcium Liquid Injection: Product Description NDC Package Size Lot#/Expiration Date First Ship Date Last Ship Date ---...

INDIANAPOLIS, Sept. 6, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the Phase III POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer (NSCLC) who were randomized to receive a combination of ALIMTA(®) (pemetrexed for injection) with bevacizumab (AVASTIN(®)) and carboplatin induction followed by ALIMTA plus bevacizumab maintenance-the ALIMTA arm-compared to the...

WEST CONSHOHOCKEN, Pa., Sept. 5, 2012 /PRNewswire/ -- BTG International Inc., the specialist healthcare company, today announces that the Centers for Medicare & Medicaid Services (CMS) has granted a temporary New Technology Add-on Payment (NTAP) for Voraxaze(®) (glucarpidase), effective 1 October 2012. This new add-on payment means that the US government will pay up to 50% of the cost of Voraxaze(®) to hospitals in addition to the standard diagnosis-related group (DRG)...